If California Rep. Brian Bilbray has his way, state inspections will no longer be required for drugs and medical devices that have already been scrutinized at the federal level.
Positron, through its wholly owned subsidiary, Manhattan Isotope Technology (MIT), has executed a memorandum of understanding with the Institute of Nuclear Research (INR) of Troitsk, Russia. MIT and INR will collaborate on strontium-82 production beginning with a pharmaceutical ingredient validation exercise in 2012.
Covidien is planning to spin off its pharmaceuticals business into a standalone public company. The unit supplies generators used to produce technetium-99m, a medical isotope, and offers an integrated system of diagnostic contrast media in prefilled syringes and injectors.
In an era of inexpensive statins, treating all Americans in the U.S. who are at intermediate risk of coronary heart disease (CHD) with statins (men and women) and aspirin (men only) is effective and less expensive than stress testing and treating only those patients with a positive result, according to a simulation study published online Dec. 5 of
Circulation.
DENVER—In the current era of nuclear stress testing, a major debate is whether pharmalogical stress testing is comparable with exercise testing. During a presentation Sept. 11 at the 16th annual American Society of Nuclear Cardiology (ASNC) scientific sessions, Brian G. Abbott, MD, medical director of nuclear cardiology at the Rhode Island Cardiology Center in Providence, R.I., said yes, particularly for diagnosing coronary artery disease.
GE Healthcare and Rapidscan Pharma Solutions have introduced regadenoson, marketed as Rapiscan, to facilitate myocardial perfusion scintigraphy (MPS) to diagnose coronary artery disease for patients unable to exercise.
Specialty pharmaceutical company Acusphere has reached an agreement with the FDA on a Special Protocol Assessment clinical trial to assess the ability of the company’s Imagify drug to detect coronary artery disease (CAD) on stress ultrasound.
RSS 
